Hikal Ltd Q3 FY26 Earnings Analysis

- Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13). - Aim to hold full-year guidance of double-digit growth in pharma despite 1H challenges (Page 14). - New molecules and product launches projected annually (2-3 new products) supporting medium-term growth (Page 6). - Robust development pipelines with 8-9 molecules progressing well; peak food and nutraceutical output expected in 18-24 months (Page 6). - Increasing CDMO early-stage RFPs and transitioning projects from development to pilot scale (Page 6). - Crop protection volumes starting to recover; flat sales expected full year (Page 5). - Animal health segment to ramp up commercial supplies over next 1-2 quarters with strong development pipeline (Pages 5, 21). - Investment in new capabilities and high-potency labs to support future growth in niche segments like oncology APIs (Pages 5, 21). - Conversion rate of pharma RFPs improving, with expected scale-up of development revenues (Page 16).

- Hikal expects a strong recovery in H2 FY26, with resumed deliveries and ramp-up in pharmaceutical business following resolution of US FDA warning letter issues. - Full-year double-digit growth in pharma is still the guidance, with deferred sales mainly shifted to H2 FY26. - Development revenue from new customers is anticipated to grow, with potential scale-up as molecules progress to market. - Crop protection segment expected to have stable performance and gradual volume recovery, though margins remain under pressure due to pricing challenges. - New investments in high-potency and specialty chemicals labs aim to drive innovation and higher-margin revenues in the mid- to long-term. - Conversion rate for pharma RFPs is around 15-20%, expected to improve to 20-25% with increased business development efforts. - Overall, Hikal remains optimistic about long-term growth through portfolio diversification, global partnerships, and compliance strengthening, but short-term earnings impacted by regulatory challenges.

- Capital expenditure (CAPEX) in H1 FY 2026 stood at Rs. 65 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacity. - Full-year CAPEX guidance is maintained at Rs. 200 crores, emphasizing disciplined allocation toward high ROI projects aligned with long-term growth strategy. - Investments include repurposing a large plant from specialty chemicals to fully pharma assets, with Phase 1 completing by end FY 2026 and Phase 2 by end calendar year, enabling capacity for new molecules. - New pilot-scale capacity is being set up at the Pune R&D center to support growth in food and nutraceutical ingredients. - Investment in a High Potent Active Pharma Ingredient (HP API) lab to enter rapidly growing segments like Oncology APIs. - Ongoing efforts include remediation CAPEX to comply with FDA requirements at Bangalore facility. - Expansion of business development manpower globally to capitalize on new opportunities.

- The company reported a healthy balance sheet with an improved debt-equity ratio of 0.55 as of H1 FY26, down from 0.59 at the start of the year. - There was no explicit mention of any planned new fundraising through debt or equity in the Q2 FY26 earnings call. - Capital expenditure guidance for the full year remains at Rs. 200 crores, focused on high-ROI projects, funded through disciplined capital allocation. - Finance costs for Q2 FY26 reduced by 13%-20% YoY, indicating effective management of existing debt. - No announcements or indications were made regarding fresh debt or equity issuances during the call or in the documented material.

- The company has seen several inquiries and RFPs from both mid-size and small-size companies, especially in the pharma CDMO segment. - Approximately $4 to $5 million in development revenue is expected from these new customers in the current year, with potential for scaling up. - The RFP conversion rate is typically between 15% to 20%, with plans to improve this to 20%-25% through enhanced BD efforts. - In the animal health segment, pre-commercial quantities are being supplied with registrations progressing; growth is anticipated as registrations complete. - No cancellations of existing purchase orders were reported despite regulatory challenges; some sales deferred but expected to be fulfilled soon. - Several new development contracts and shortlisted RFPs indicate a strong and diversified project pipeline.